Anyone in the United States who wants to know if she has mutations in two breast cancer genes has little choice of where to be tested. One company alone has patents on the genes, and that company pretty much controls the market. Heidi Rehm, HMS assistant professor of pathology at Brigham and Women’s Hospital, is quoted.
